- Home
- SVRN vs CLDI Comparison
SVRN vs CLDI Comparison
Compare SVRN & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRN
- CLDI
- Stock Information
- Founded
- SVRN 2021
- CLDI 2014
- Country
- SVRN Greece
- CLDI United States
- Employees
- SVRN N/A
- CLDI N/A
- Industry
- SVRN Marine Transportation
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVRN Consumer Discretionary
- CLDI Health Care
- Exchange
- SVRN Nasdaq
- CLDI Nasdaq
- Market Cap
- SVRN 9.1M
- CLDI 9.9M
- IPO Year
- SVRN N/A
- CLDI N/A
- Fundamental
- Price
- SVRN $1.41
- CLDI $1.49
- Analyst Decision
- SVRN
- CLDI
- Analyst Count
- SVRN 0
- CLDI 0
- Target Price
- SVRN N/A
- CLDI N/A
- AVG Volume (30 Days)
- SVRN 153.3K
- CLDI 232.3K
- Earning Date
- SVRN 12-19-2025
- CLDI 11-13-2025
- Dividend Yield
- SVRN N/A
- CLDI N/A
- EPS Growth
- SVRN N/A
- CLDI N/A
- EPS
- SVRN N/A
- CLDI N/A
- Revenue
- SVRN $19,435,000.00
- CLDI N/A
- Revenue This Year
- SVRN N/A
- CLDI N/A
- Revenue Next Year
- SVRN N/A
- CLDI N/A
- P/E Ratio
- SVRN N/A
- CLDI N/A
- Revenue Growth
- SVRN N/A
- CLDI N/A
- 52 Week Low
- SVRN $1.07
- CLDI $1.10
- 52 Week High
- SVRN $79.25
- CLDI $27.63
- Technical
- Relative Strength Index (RSI)
- SVRN N/A
- CLDI 53.86
- Support Level
- SVRN N/A
- CLDI $1.29
- Resistance Level
- SVRN N/A
- CLDI $1.56
- Average True Range (ATR)
- SVRN 0.00
- CLDI 0.11
- MACD
- SVRN 0.00
- CLDI 0.01
- Stochastic Oscillator
- SVRN 0.00
- CLDI 96.29
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.